Hemispherx Biopharma Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat

Published: Aug 26, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August 22, 2013, Professor Dr. Juergen A. Richt, DVM, Ph.D., a scientific advisor to Hemispherx, described his experiments in human lung cells evidencing that Alferon N Injection®, the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, is biologically active, in low doses, against various classes of viruses occurring naturally in animals and humans. Dr. Richt is the Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases, the Regents Distinguished Professor at Kansas State University, and an Eminent Scholar of Kansas Bioscience Association.

Help employers find you! Check out all the jobs and post your resume.

Back to news